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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
vitamin K2 and contribution to the normal function of the heart and blood 
vessels (ID 125, further assessment) pursuant to Article 13(1) of Regulation 
(EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, pursuant to Article 13 of Regulation (EC) No 1924/2006, 
the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a health 
claim related to vitamin K2 and contribution to the normal function of the heart and blood vessels. The food 
constituent that is the subject of the claim, vitamin K2, is sufficiently characterised. The claimed effect, 
contribution to the normal function of the heart and blood vessels, is a beneficial physiological effect. The 
proposed target population is the general population. In weighing the evidence, the Panel took into account the 
absence of human intervention studies from which conclusions could be drawn for the scientific substantiation of 
the claim, the inconsistency of the results reported in two cross-sectional studies regarding arterial calcification in 
women, that the results of two prospective cohort studies are in conflict regarding the risk of coronary heart 
disease associated with vitamin K2 intakes, that high intakes of vitamin K2 were associated with a significantly 
lower degree of aortic calcification in one prospective cohort study after adjustment for confounders, and that the 
evidence provided for a proposed mechanism is weak. On the basis of the data presented, the Panel concludes 
that a cause and effect relationship has not been established between the dietary intake of vitamin K2 and 
contribution to the normal function of the heart and blood vessels.  
© European Food Safety Authority, 2012 
KEY WORDS 
Vitamin K, menaquinones, heart, blood vessels, calcification, health claims. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2012-00125, adopted on 26 April 2012. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen.  
 
Vitamin K2 and contribution to the normal function  
of the heart and blood vessels (further assessment) 
 
2 EFSA Journal 2012;10(6):2714 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
regulation (EC) No 1924/2006. The Commission has agreed with EU Member States that a certain 
number of Article 13 health claims would be eligible for further assessment by EFSA in order to be 
able to take a final decision on whether or not to include these claims in the list of permitted health 
claims. This opinion addresses the scientific substantiation of a health claim in relation to vitamin K2 
and contribution to the normal function of the heart and blood vessels. The scientific substantiation is 
based on the information provided by the Member States in the consolidated list of Article 13 health 
claims, references that EFSA has received from Member States or directly from stakeholders and the 
additional information provided by the competent Authority of the United Kingdom for further 
assessment of this claim. 
The food constituent that is the subject of the health claim is vitamin K2. The Panel considers that 
vitamin K2 is sufficiently characterised. 
The claimed effect, which is eligible for further assessment, is normal function of the heart and blood 
vessels. The proposed target population is the general population. The Panel considers that 
contribution to the normal function of the heart and blood vessels is a beneficial physiological effect. 
In its earlier opinion the Panel considered three cross-sectional studies and one prospective cohort 
study which investigated the relationship between vitamin K intake and arterial calcification or the 
elastic properties of the arteries, which may interfere with normal vascular structure and function. In 
the framework of further assessment one prospective cohort study on the association between vitamin 
K2 intakes and the risk of coronary heart disease and three unpublished human intervention studies 
which investigated the effect of vitamin K2 on blood concentrations of a matrix Gla-protein (MGP) 
and two animal studies on the mechanisms by which vitamin K2 could exert the claimed effect were 
provided. 
This evaluation is based on the scientific references provided in the present and the previous 
submissions which addressed the relationship between vitamin K2 intake and changes in 
vascular/heart function (e.g. coronary heart disease) or changes in vascular/heart structure leading to 
changes in vascular/heart function (e.g. arterial calcification). Scientific references on the mechanisms 
by which vitamin K2 could exert the claimed effect in the target population were also considered.  
Two prospective cohort studies investigated the association between vitamin K2 intakes and 
incidence of coronary heart disease and the degree of aortic calcification. The Panel notes that the 
results of the two prospective cohort studies are in conflict regarding the risk of coronary heart 
disease associated to vitamin K2 intakes, and that high intakes of vitamin K2 were associated with a 
significantly lower degree of aortic calcification after adjustment for confounders in one prospective 
cohort study. 
Two cross-sectional studies investigated the relationship between vitamin K intake and arterial 
calcification. The Panel notes that one cross-sectional study reported that vitamin K2 intake was 
inversely related to the presence of coronary calcification while the other showed no association 
between vitamin K2 intake and breast arterial calcification, after adjustment for confounders. 
The proposed mechanism by which vitamin K2 could exert the claimed effect is by contributing to the 
vitamin K-dependent activation (carboxylation) of MGP, a matrix Gla-protein which has been 
identified in vascular tissue. Increased levels of carboxylated MGP would reduce vascular 
calcification and decrease the risk of vascular (including coronary) events.  
There is some evidence for a role of MGP in preventing calcification of soft tissues. In an MGP 
knock-out mouse model, spontaneous calcification of soft tissues (mostly arteries) occurred. Also in 
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the Keutel syndrome, which results from a mutation of the gene encoding the human MGP, patients 
display several of the same features as the knockout mice, including abnormal calcification of ear and 
nose cartilage, and of the respiratory tract. However, whether changes in vitamin K2 intakes may 
induce changes in MGP carboxylation, which in turn could affect vascular function (e.g. calcification) 
or the risk of vascular events, has not been established. 
In weighing the evidence, the Panel took into account the absence of human intervention studies from 
which conclusions could be drawn for the scientific substantiation of the claim, the inconsistency of 
the results reported in two cross-sectional studies regarding arterial calcification in women, that the 
results of two prospective cohort studies are in conflict regarding the risk of coronary heart disease 
associated with vitamin K2 intakes, that high intakes of vitamin K2 were associated with a 
significantly lower degree of aortic calcification in one prospective cohort study after adjustment for 
confounders, and that the evidence provided for a proposed mechanism is weak. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the dietary intake of vitamin K2 and contribution to the normal function of 
the heart and blood vessels. 
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel on a health claim pursuant to Article 13 of Regulation (EC) 
No 1924/2006
4
 in which the Panel concluded that the evidence provided was insufficient to establish 
a cause and effect relationship between the dietary intake of vitamin K and the normal function of the 
heart and blood vessels (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009), 
EFSA received additional information from the competent Authority of the United Kingdom for 
further assessment of this claim.  
ASSESSMENT 
1. Characterisation of the food/constituent (ID 125) 
The food constituent that was the subject of the health claim in the initial assessment was vitamin K 
(i.e. phylloquinone and menaquinones) (EFSA Panel on Dietetic Products Nutrition and Allergies 
(NDA), 2009). Upon request, in the framework of further assessment the present evaluation refers to 
vitamin K2 (i.e. menaquinones) only, which is a well recognised nutrient and is measurable in foods 
by established methods. 
Vitamin K is a family of structurally similar, fat soluble, 2-methyl-1,4-naphthoquinones, including 
phylloquinone (2-methyl-3-phytyl-1,4-naphthoquinone, vitamin K1) and menaquinones (collectively 
known as vitamin K2). Menaquinones are a series of compounds containing an unsaturated side chain 
with differing numbers of isoprenyl units at the 3 position in the methyl-1,4-naphthoquinone nucleus. 
Depending on the number of isoprenyl units, the individual compounds are designated as 
menaquinone-n (MK-n). Menaquinones (vitamin K2) occur naturally in foods such as meat, liver, 
fish, butter, egg yolk, natto (which consists of fermented soy beans), and dairy products including 
cheese and curd cheese, and can also be produced by many bacteria (MK-7 to MK-10) (Schurgers and 
Vermeer, 2000).  
Menaquinones (vitamin K2) are naturally present in foods and have been authorised for addition to 
foods and for use in food supplements (Annex II of Regulation (EC) No 1925/2006
5
 and Annex II of 
Directive 2002/46/EC
6
). This evaluation applies to vitamin K2 naturally present in foods and added to 
foods, including food supplements (Annex II of Regulation (EC) No 1925/2006 and Annex II of 
Directive 2002/46/EC).  
The Panel considers that the food constituent, vitamin K2, which is the subject of the health claim, is 
sufficiently characterised.  
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
6  Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
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2. Relevance of the claimed effect to human health (ID 125) 
The claimed effect, which is eligible for further assessment, is normal function of the heart and blood 
vessels (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009). The proposed target 
population is the general population.  
A request was made, in the framework of further assessment, to interpret the claimed effect as 
“vascular health”. The Panel notes that this claimed effect is not sufficiently defined for a scientific 
evaluation, that ID 125 has been previously assessed as a claim on the normal function of the heart 
and blood vessels, and that this is the claim which is eligible for further assessment.  
The Panel considers that contribution to the normal function of the heart and blood vessels is a 
beneficial physiological effect.  
3. Scientific substantiation of the claimed effect (ID 125)  
In its earlier opinion (for ID 124, 125 and 2880) (EFSA Panel on Dietetic Products Nutrition and 
Allergies (NDA), 2009), the Panel considered three cross-sectional studies (Beulens et al., 2009; Jie et 
al., 1995; Maas et al., 2007) and one prospective cohort study (Geleijnse et al., 2004) which 
investigated the relationship between vitamin K intake and arterial calcification or the elastic 
properties of the arteries, which may interfere with normal vascular structure and function. One of the 
studies did not report on vitamin K2 intakes specifically and will not be considered further in this 
evaluation, as requested in the application for further assessment (Jie et al., 1995). In addition, one 
animal study (Luo et al., 1997), which reported on a Matrix Gla Protein (MGP) knockout mouse 
model, and one human study (Munroe et al., 1999) reporting on a mutation of the gene encoding 
human MGP, were considered for the scientific substantiation of the claim.  
In the framework of the further assessment, one prospective cohort study on the association between 
vitamin K2 intakes and the risk of coronary heart disease (CHD) (Gast et al., 2009), as well as three 
unpublished human intervention studies which investigated the effect of vitamin K2 on blood 
concentrations of MGP (Braam and Vermeer, 2011, unpublished; Moschonis et al., 2011, 
unpublished; Vermeer, 2008, unpublished) and two animal studies on the mechanisms by which 
vitamin K2 could exert the claimed effect (Schurgers et al., 2007; Spronk et al., 2003), were provided. 
This evaluation is based on the scientific references provided in the present and the previous 
submissions which addressed the relationship between vitamin K2 intake and changes in 
vascular/heart function (e.g. CHD) or changes in vascular/heart structure leading to changes in 
vascular/heart function (e.g. arterial calcification). Scientific references on the mechanisms by which 
vitamin K2 could exert the claimed effect in the target population were also considered.  
Two prospective cohort studies investigated the association between vitamin K2 intakes and 
incidence of CHD (Gast et al., 2009; Geleijnse et al., 2004) and the degree of aortic calcification 
(Geleijnse et al., 2004).  
A Dutch prospective cohort study (Geleijnse et al., 2004) was conducted in 7,983 men and women 
aged 55 years and over, who completed at baseline a semi-quantitative food-frequency questionnaire 
to assess foods and beverages consumed more than once a month during the preceding year. At 
baseline, calcified deposits were detected in the abdominal aorta parallel and anterior to the lumbar 
spine on a lateral radiographic film, and the severity of this calcification was graded as “absent or 
mild” (≤1 cm calcification), “moderate” (>1 and <5 cm) or “severe” (≥5 cm). Risk of non fatal 
myocardial infarction, of incident CHD and of CHD mortality during follow-up was examined. After 
exclusion of institutionalised subjects, subjects with no or unreliable dietary data, and subjects with a 
history of myocardial infarction, 4,807 individuals, with a mean follow-up of 7.2 years, were included 
in the analysis for coronary events. After exclusion of subjects with no or unreliable baseline 
Vitamin K2 and contribution to the normal function  
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radiographic films, 4,473 subjects were included in the analysis on abdominal aortic calcification. The 
risk ratios (RR) of coronary events in energy-adjusted tertiles of intake of vitamin K2 were studied in 
a Cox regression model and the association (odd ratios, OR) between the tertiles of intake and 
moderate or severe aortic calcification was assessed in a multivariate logistic regression model. 
Analyses were performed with adjustment for age, sex and total energy intake (model 1), and with 
additional adjustment for Body Mass Index (BMI), diabetes mellitus, smoking status, pack/year of 
cigarette smoking, category of education, and intakes of alcohol, calcium, flavonols, and saturated and 
polyunsaturated fatty acids (model 2). In this population, 64.3 % (n=2,874), 30.4 % (n=1,359) and 
5.4 % (n=240) of subjects had “absent or mild”, “moderate” or “severe” calcification, respectively. 
Compared with the first tertile of vitamin K2 intake, high intakes of vitamin K2 (third tertile only) 
were associated with a lower incidence of CHD only in model 2 (RR: 0.59, 95 % CI: 0.40-0.86), and 
with a lower CHD mortality (models 1 and 2), but not with a lower risk of non fatal myocardial 
infarction (models 1 and 2). Compared with the first tertile of vitamin K2 intake, high intakes of 
vitamin K2 (third tertile only) were associated with a lower risk of severe aortic calcification (models 
1 and 2; OR: 0.48, 95 % CI: 0.32-0.71 for model 2). No significant association was observed with 
moderate calcification. Results did not change with further adjustment for intakes of vitamin E, 
vitamin C, beta-carotene and fibre. The Panel notes that higher intakes of vitamin K2 were associated 
with a significantly lower degree of aortic calcification and lower incidence of CHD in this study, 
after adjustment for confounders. 
Another Dutch prospective cohort study (Gast et al., 2009) was conducted in 17,357 women aged 49-
70 years, with a mean follow-up of 8.1 years, and investigated the relationship between vitamin K2 
intake and risk of CHD. After exclusion of women with dietary energy intake below 500 kcal/day or 
above 6,000 kcal/day, with no baseline general questionnaires or no retrievable data on vital status, or 
with either a reported history of CHD or cerebrovascular events or a reported use of vitamin K 
antagonists, 16,057 post-menopausal women completed a food frequency questionnaire at baseline to 
estimate intakes of vitamin K2 during the year preceding enrolment in the study. Cox proportional 
hazards regression models were used to estimate the hazard ratio (HR) for coronary events, in a 
univariate analysis (model 1), after adjustment for age at baseline (model 2), after additional 
adjustment for BMI, smoking status, presence of diabetes, hypertension and hypercholesterolaemia, 
and energy-adjusted alcohol intake (model 3), after further adjustment for dietary factors, i.e. energy 
and energy-adjusted intakes of saturated and polyunsaturated fatty acids (model 4), or after further 
adjustment for calcium intakes, which were found to be strongly correlated with vitamin K2 intakes 
(model 5). The HR for risk of CHD per 10 µg increase in vitamin K2 intake was significantly reduced 
in models 1 and 2, but not in model 3. The HR was 0.92 (95 % CI: 0.83 to 1.01) in model 5, and was 
0.91 (95 % CI: 0.85 to 1.00) when calcium was excluded from the model (model 4). The Panel notes 
that higher intakes of vitamin K2 were not significantly associated with a reduced risk of CHD in this 
study, after adjustment for confounders.  
The Panel notes that the results of two prospective cohort studies (Gast et al., 2009; Geleijnse et al., 
2004) are in conflict regarding the risk of CHD associated to vitamin K2 intakes, and that high intakes 
of vitamin K2 were associated with a significantly lower degree of aortic calcification after 
adjustment for confounders in one prospective cohort study (Geleijnse et al., 2004). 
Two cross-sectional studies (Beulens et al., 2009; Maas et al., 2007) investigated the relationship 
between vitamin K intake and arterial calcification in women in random samples of the Dutch cohort 
described by Gast et al. (2009).  
The study by Beulens et al. (2009) was undertaken on post-menopausal women (n=564, after 
exclusion of eight subjects with missing information on coronary calcification and one subject with 
missing information on vitamin K intakes) who did not use contraceptives or were not on hormone 
replacement therapy and who underwent (seven to eleven years after enrolment) a multislice multi-
detector computed tomography, from which coronary arterial calcium was quantified using the 
Vitamin K2 and contribution to the normal function  
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Agatston calcium score. Presence of calcium in the coronary arteries was defined as a score >0. 
Energy-adjusted menaquinone intakes (estimated during the year preceding enrolment in the study) 
were categorised in quartiles. Prevalence ratios of coronary calcification for these quartiles were 
estimated using Poisson regression, and were adjusted for age (model 1), as well as smoking status, 
presence of diabetes and hypertension, categories of education, HDL- and LDL-cholesterol (model 2), 
and, in addition, alcohol consumption and energy-adjusted intakes of protein, calcium and fibre 
(model 3). Sixty-two percent of the women had coronary calcification. The prevalence ratio of 
coronary calcification was significantly lower only for the highest quartile of menaquinone intake, 
compared to the lowest, in models 1 and 3 (respectively 0.82, 95 % CI: 0.68-0.99; and 0.80, 95 % CI: 
0.65-0.98). The Panel notes that vitamin K2 intake was inversely related to the presence of coronary 
calcification, after adjustment for confounders. 
The study by Maas et al. (2007) was conducted in women for whom the frozen blood samples and the 
baseline mammogram, on which calcium deposits along the breast arteries were searched for in one or 
both breasts, were retrieved. After exclusion of 18 subjects with reported use of vitamin K antagonists 
and of 29 subjects with no blood sample or baseline general questionnaires, 1,689 women were 
considered in the analysis. Mean K2 intakes were calculated for each quartile, and for women with or 
without breast arterial calcification. Adjustment for age, smoking, diabetes, energy-adjusted intakes of 
saturated, monounsaturated and polyunsaturated fatty acids and protein, and for intakes of calcium 
was done with univariate analysis of variance (ANOVA) (general linear model). The prevalence of 
breast arterial calcification was not statistically significantly different (OR 0.7, 95 % CI: 0.5-1.1) 
between the highest (9 %) and the lowest (13 %) quartile of vitamin K2 intake. After adjustment for 
confounders, mean vitamin K2 intake was not statistically significantly different between participants 
with or without breast arterial calcification. The Panel notes that this study showed no association 
between vitamin K2 intake and breast arterial calcification, after adjustment for confounders. 
The Panel notes that one cross-sectional study reported that vitamin K2 intake was inversely related to 
the presence of coronary calcification (Beulens et al., 2009), while the other (Maas et al., 2007) 
showed no association between vitamin K2 intake and breast arterial calcification, after adjustment 
for confounders. 
The proposed mechanism by which vitamin K2 could exert the claimed effect is by contributing to the 
vitamin K-dependent activation (carboxylation) of MGP, a matrix Gla-protein which has been 
identified in vascular tissue. Increased levels of carboxylated MGP would reduce vascular 
calcification and decrease the risk of vascular (including coronary) events.  
There is some evidence for a role of MGP in preventing calcification of soft tissues. In an MGP 
knock-out mouse model, spontaneous calcification of soft tissues (mostly arteries) occurred (Luo et 
al., 1997). Also in the Keutel syndrome, which results from a mutation of the gene encoding the 
human MGP, patients display several of the same features as the knockout mice, including abnormal 
calcification of ear and nose cartilage, and of the respiratory tract (Munroe et al., 1999). However, 
whether changes in vitamin K2 intakes may induce changes in MGP carboxylation, which in turn 
could affect vascular function (e.g. calcification) or the risk of vascular events, has not been 
established.  
Three additional randomised, placebo-controlled, parallel intervention studies investigated the effects 
of vitamin K2 supplementation on blood concentrations of (uncarboxylated/carboxylated) MGP 
(Braam and Vermeer, 2011, unpublished; Moschonis et al., 2011, unpublished; Vermeer, 2008, 
unpublished). The Panel notes that these studies do not provide any information about how, and to 
which extent, changes in (uncarboxylated/carboxylated) MGP may affect vascular function, and 
considers that no conclusions can be drawn from these studies for the scientific substantiation of the 
claim.  
Vitamin K2 and contribution to the normal function  
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As regards the animal studies, one study (Spronk et al., 2003) investigated the effects of diets 
containing warfarin and vitamin K1, vitamin K2 (MK-4, 1.5 mg per g of food), or both, on 
calcification of the aorta and carotid arteries in male rats. The Panel considers that no conclusions can 
be drawn from a study using a fixed combination for the substantiation of a claim on vitamin K2 
alone.  
The second study (Schurgers et al., 2007) investigated the effects of diets with different contents of 
vitamin K1 or vitamin K2 on arterial calcium content and stiffness, total plasma MGP, MGP deposits 
in vascular tissues, and the content of vitamin K1 and K2 in the aorta, in male rats with preformed 
arterial calcification. Thirty rats received a six-week diet containing warfarin and 1.5 mg vitamin K1 
per g of food (“W&K”) to induce arterial calcification, while the controls (n=18) received vitamin K1 
without warfarin. Six rats from the control group were killed to measure the baseline arterial calcium 
content, and after the six weeks of treatment, six additional control rats and six treated rats were killed 
to monitor the effect of treatment, while the remaining control rats continued their diet for six 
additional weeks. The remaining treated rats were divided into four groups (n=6 each), which either 
continued for six additional weeks the same “W&K” diet with warfarin and vitamin K1, or received 
diets without warfarin for six weeks, but either with vitamin K1 (“normal” and “high K1 groups”), or 
with 100 µg vitamin K2 per g of food (“high K2 group” receiving MK-4). Antibodies were raised 
against, respectively, total, carboxylated and uncarboxylated MGP. Calcium content was assessed in 
the abdominal aorta and left carotid artery, and the right carotid artery was used for monitoring 
distensibility and compliance. Immunohistochemistry was performed on the aortic arch and thoracic 
aorta. The Panel notes that although the outcomes assessed in this study were related to the claimed 
effect, no information was provided to establish the validity of this animal model for the scientific 
substantiation of the claim in humans. 
The Panel considers that the evidence provided in these animal studies is not sufficient to predict the 
occurrence of an effect of the dietary intake of vitamin K2 on contribution to the normal function of 
the heart and blood vessels in humans. 
In weighing the evidence, the Panel took into account the absence of human intervention studies from 
which conclusions could be drawn for the scientific substantiation of the claim, the inconsistency of 
the results reported in two cross-sectional studies regarding arterial calcification in women, that the 
results of two prospective cohort studies are in conflict regarding the risk of CHD associated with 
vitamin K2 intakes, that high intakes of vitamin K2 were associated with a significantly lower degree 
of aortic calcification in one prospective cohort study after adjustment for confounders, and that the 
evidence provided for a proposed mechanism is weak. 
The Panel concludes that a cause and effect relationship has not been established between the dietary 
intake of vitamin K2 and contribution to the normal function of the heart and blood vessels. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, vitamin K2, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect, which is eligible for further assessment, is normal function of the heart 
and blood vessels. The proposed target population is the general population. Contribution to 
the normal function of the heart and blood vessels is a beneficial physiological effect.  
 A cause and effect relationship has not been established between the dietary intake of 
vitamin K2 and contribution to the normal function of the heart and blood vessels. 
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DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment (No: 
EFSA-Q-2012-00125). The scientific substantiation is based on the information provided by the 
Member States in the consolidated list of Article 13 health claims, references that EFSA has received 
from Member States or directly from stakeholders and the additional information provided by the 
competent Authority of the United Kingdom for further assessment of this claim (available at: 
http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
7
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
8
  
Foods are commonly involved in many different functions
9
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
7  OJ L12, 18/01/2007 
8  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
9  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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GLOSSARY AND ABBREVIATIONS 
ANOVA Analysis of variance 
BMI  Body mass index 
CHD  Coronary heart disease 
CI  Confidence interval 
Gla  Glutamic acid 
HDL  High density lipoproteins 
HR  Hazard ratio 
LDL  Low density lipoproteins 
MGP  Matrix Gla Protein 
MK  Menaquinone 
OR  Odds ratio 
RR  Risk ratio 
